Focused on novel, nanotechnology-based therapeutics

Oliver Fetzer, Ph.D.
President and Chief Executive Officer

David P. DeMagistris, Ph.D.
Senior Vice President, Product Development

Scott Eliasof, Ph.D.
Vice President, Research

Edward Garmey, M.D.
Chief Medical Officer and Senior Vice President

Alexandra Glucksmann, Ph.D.
Senior Vice President, Research and Development

Christopher D. T. Guiffre, J.D.
Senior Vice President and Chief Business Officer

Chris joins Cerulean to lead our partnering activities after serving as President and Chief Executive Officer of Alvos Therapeutics, Inc., a biopharmaceutical company dedicated to developing “guided therapeutics” that destroy cancer cells while sparing normal tissues.  Previously, Chris was Chief Business Officer at Hydra Biosciences, Inc. where he led the company’s partnering activities culminating in a transformational deal for the company’s lead TRP ion channel program.  Before Hydra, Chris was Senior Vice President, General Counsel and Secretary at Cubist Pharmaceuticals, Inc., where he oversaw legal, IP, Compliance, Risk Management, Government Affairs, Regulatory Affairs, Quality Assurance, and Quality Control functions and worked closely with the Finance and BD functions on the company’s financing and business development transactions during the company’s highly successful transition from an R&D company to a fully integrated commercial pharmaceutical company.  Prior to his time at Cubist, Chris held positions of increasing responsibility at Renaissance Worldwide, Inc., including Vice President, General Counsel and Clerk, and he was an associate at Bingham, Dana & Gould (n/k/a Bingham McCutchen).

Chris earned a B.S. from Babson College, a J.D. from Boston College Law School, and an M.B.A. from Boston College Carroll School of Management.

Karen Roberts
Senior Vice President, Finance and Administration

Jean Silveri, J.D.
Senior Vice President, General Counsel

Marc Wolfgang
Vice President, Pharmaceutical Sciences and Manufacturing

Cissy Young, Ph.D.
Director, Strategy and Business Development